Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097329 | 1.00 | AHCY (0.52) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL7140801 | 1.00 | AHCY (0.52) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL9311466 | 0.94 | AHCY (0.54) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL9310980 | 0.87 | AHCY (0.50) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL9309144 | 0.86 | AHCY (0.65) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL23358348 | 0.86 | AHCY (0.48) | AHCYLMNATP53PDE4DPNP | |
| Hydrochloric Acid SCHEMBL23358343 | 0.85 | AHCY (0.47) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL9423943 | 0.83 | PDE4D (0.62) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL19503470 | 0.83 | PDE4D (0.62) | AHCYLMNATP53PDE4DPNP | |
| SCHEMBL10513742 | 0.82 | AHCY (0.72) | AHCYLMNATP53NT5EADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0628044-B1 | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 2003-07-23 | — | — | EP | disclosed |
| US-6392085-B2 | INTERMEDIATES USEFUL IN PRODUCTION OF DRUGS FOR TREATING VIRAL INFECTIONS (HEPATITIS B) | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20010008946-A1 | THERAPEUTIC NUCLEOSIDES | SMITHKLINE BEECHAM CORPORATION | 2001-07-19 | — | — | US | disclosed |
| US-5840990-A | ENANTIOMORPHS AND VIRICIDES FOR CHEMICAL INTERMEDIATES | GLAXO WELLCOME INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5808147-A | Therapeutic nucleosides | GLAXO WELLCOME INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5641889-A | AMINO-HYDROXY-CYCLOPENTENE INTERMEDIATES FOR PURINE NUCLEOSIDES; VIRICIDES | GLAXO WELLCOME INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0628044-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993017020-A2 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008946-A1 | THERAPEUTIC NUCLEOSIDES | NUDT1, PNP, TYMP | AHCY 439/4885LMNA 1266/4885TP53 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.